BV
Schedule 13G filing
Biotechnology Value Fund L.P. disclosed a 14.3% stake in FHTX
Biotechnology Value Fund L.P. reported owning 14.3% of Foghorn Therapeutics Inc. (FHTX) (8,507,000 shares) in a Schedule 13G filed Oct 5, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 5, 2026
- Source
- Schedule 13G
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.